E-health HTAs published in Scotland in October 2021

24

Nov 2021

In October 2021, the Scottish Health Technology Group, SHTG, released two Innovative Medical Technology Overviews for e-health technologies.

The Scottish asynchronous digital dermatology appointment service (DDAS) is an asynchronous virtual dermatology clinic that allows patients to submit images of their skin condition, along with answers to specific questions about their skin condition, to a dermatology specialist (link).

The SHTG concluded that the DDAS has provided continuity of access to dermatology services in three Scottish health boards during the COVID-19 pandemic. Boards that have implemented the DDAS have reported no problems associated with recruiting older patients, children, or patients with limited technological skills. All boards have alternatives in place for patients who do not wish to use the DDAS. The planned roll-out of the DDAS to additional health boards across Scotland should provide more data, with the potential for further performance and economic analyses of the service.

The Dxcover™ Brain Cancer Liquid Biopsy is a biopsy test that uses machine learning to identify and compare patterns in the biochemical profile of serum from patients with and without brain cancer (link).

The SHTG concluded that the exploratory cost-effectiveness model based on early pre-trial data suggested the Dxcover™ test was likely cost-effective if the prevalence of brain cancer in the primary care population being considered for referral was 1% or higher. A test cost of £100 was assumed. Further work is required to confirm the accuracy of the test in a primary care population; to assess the effect of the test on patient pathways; to examine the impact on patient outcomes; to define the cost-effectiveness.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

23

Nov 2021

In late October 2021, the Treatment Council (Behandlingsråd) published three topics chosen for developing the so-called major analyses (større analyser) in 2022. The selected topics include patient-centered diabetes technology, hand-held focused ultrasound in emergency medicine, and artificial intelligence as decision support for colonoscopy.

Read more

18

Nov 2021

In October 2021, the National Institute for Health and Care Excellence (NICE) published three new Interventional Procedure Guidance (genicular artery embolization for pain from knee osteoarthritis, laparoscopic renal denervation for loin pain hematuria syndrome, percutaneous endovascular forearm arteriovenous fistula creation for hemodialysis access), and one new Medical Technologies Guidance (DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography). Also, two new clinical guidelines were published.

Read more

16

Nov 2021

In late October 2021, the BfArM (Federal Institute for Drugs and Medical Devices) has published the final version of the 2022 OPS procedure coding classification. The OPS, together with the ICD-10-GM (International Statistical Classification of Diseases and Related Health Problems, 10th revision, German Modification), forms the basis for the reimbursement systems in outpatient and inpatient care.

Read more

15

Nov 2021

In November 2021, NHSX announced projects to improve digital pathways awarded for funding from the newly created Adoption Fund. Funding opportunities will support Integrated Care Systems (ICSs) with initiatives to test out digital pathways across various specialty areas, including gastroenterology, musculoskeletal, and cardiology. A total of 35 applications were successful and will share funding of £6.5 million.

Read more

09

Nov 2021

In early October 2021, three more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, 23 health apps are now available at the DiGA Directory.

Read more